• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

衰老及阿尔茨海默病型痴呆中的大脑与大脑单胺氧化酶

Brain and brain monoamine oxidase in aging and in dementia of Alzheimer's type.

作者信息

Oreland L, Gottfries C G

出版信息

Prog Neuropsychopharmacol Biol Psychiatry. 1986;10(3-5):533-40. doi: 10.1016/0278-5846(86)90023-0.

DOI:10.1016/0278-5846(86)90023-0
PMID:3797686
Abstract

Brain MAO-B activity increases with age. The rate of increase varies in different brain regions. Brain MAO-A activity does not change with age in man and is decreased in the rat. Brain MAO-B activity in AD/SDAT is higher than in age-matched controls. The increased MAO-B activity in aging is due to an increased concentration of otherwise unchanged extrasynaptosomal MAO-B. The increase in brain MAO-B activity with age and in AD/SDAT is more pronounced in white matter than in gray matter. Platelet MAO is increased in patients with AD/SDAT.

摘要

脑单胺氧化酶B(MAO-B)活性随年龄增长而增加。不同脑区的增加速率有所不同。在人类中,脑单胺氧化酶A(MAO-A)活性不随年龄变化,而在大鼠中则降低。阿尔茨海默病/老年期痴呆(AD/SDAT)患者的脑MAO-B活性高于年龄匹配的对照组。衰老过程中MAO-B活性增加是由于突触外MAO-B浓度增加,而其本身未发生变化。随着年龄增长以及在AD/SDAT中,脑MAO-B活性在白质中的增加比在灰质中更明显。AD/SDAT患者的血小板MAO增加。

相似文献

1
Brain and brain monoamine oxidase in aging and in dementia of Alzheimer's type.衰老及阿尔茨海默病型痴呆中的大脑与大脑单胺氧化酶
Prog Neuropsychopharmacol Biol Psychiatry. 1986;10(3-5):533-40. doi: 10.1016/0278-5846(86)90023-0.
2
Brain gamma-aminobutyrate aminotransferase (GABA-T) and monoamine oxidase (MAO) in patients with Alzheimer's disease.
J Neural Transm Park Dis Dement Sect. 1992;4(3):227-40. doi: 10.1007/BF02260906.
3
Platelet MAO-B activity as a marker of behavioural characteristics in dementia disorders.血小板单胺氧化酶B活性作为痴呆症行为特征的标志物。
Aging (Milano). 1994 Jun;6(3):201-7. doi: 10.1007/BF03324240.
4
Comparative platelet proteome analysis reveals an increase of monoamine oxidase-B protein expression in Alzheimer's disease but not in non-demented Parkinson's disease patients.比较血小板蛋白质组分析显示,阿尔茨海默病患者中单胺氧化酶-B 蛋白表达增加,而未痴呆的帕金森病患者中则没有。
J Proteomics. 2012 Apr 3;75(7):2080-92. doi: 10.1016/j.jprot.2012.01.014. Epub 2012 Jan 17.
5
Vitamin B12-induced reduction of platelet monoamine oxidase activity in patients with dementia and pernicious anaemia.维生素B12对痴呆和恶性贫血患者血小板单胺氧化酶活性的降低作用。
Eur Arch Psychiatry Clin Neurosci. 1991;240(4-5):288-91. doi: 10.1007/BF02189542.
6
Dopaminergic system and monoamine oxidase-B activity in Alzheimer's disease.阿尔茨海默病中的多巴胺能系统与单胺氧化酶-B活性
Neurobiol Aging. 1988 May-Jun;9(3):245-52. doi: 10.1016/s0197-4580(88)80061-7.
7
Low B12 levels related to high activity of platelet MAO in patients with dementia disorders. A retrospective study.痴呆症患者中低维生素B12水平与血小板单胺氧化酶高活性相关。一项回顾性研究。
Acta Psychiatr Scand. 1988 Oct;78(4):451-7. doi: 10.1111/j.1600-0447.1988.tb06366.x.
8
Differential changes in monoamine oxidase A and B activity in the aging rat brain.衰老大鼠大脑中单胺氧化酶A和B活性的差异变化。
J Neurochem. 1980 Nov;35(5):1026-32. doi: 10.1111/j.1471-4159.1980.tb07856.x.
9
Alterations in brain monoamine oxidase activity in aging, Alzheimer's disease, and Pick's disease.衰老、阿尔茨海默病和皮克病中脑单胺氧化酶活性的改变。
Arch Neurol. 1991 Jul;48(7):718-21. doi: 10.1001/archneur.1991.00530190064017.
10
Platelet tritiated imipramine binding and MAO activity in Alzheimer's disease patients with agitation and delusions.伴有激越和妄想的阿尔茨海默病患者血小板中氚标记丙咪嗪结合及单胺氧化酶活性
Psychiatry Res. 1988 Sep;25(3):311-22. doi: 10.1016/0165-1781(88)90101-1.

引用本文的文献

1
Aryl Hydrocarbon Receptor Establishes a Delicate Balance between the Level of the Trace Amine Tryptamine and Monoamine Oxidase Activity in the Brain and Periphery in Health and Conditions such as Neurodegenerative, Neurodevelopmental, and Psychiatric Disorders.芳烃受体在健康状态以及神经退行性、神经发育性和精神性疾病等情况下,在大脑和外周的痕量胺色胺水平与单胺氧化酶活性之间建立了微妙的平衡。
Curr Neuropharmacol. 2025;23(11):1328-1350. doi: 10.2174/011570159X340635241022113450.
2
Overview of the Neuroprotective Effects of the MAO-Inhibiting Antidepressant Phenelzine.单胺氧化酶抑制型抗抑郁药苯乙肼的神经保护作用概述。
Cell Mol Neurobiol. 2022 Jan;42(1):225-242. doi: 10.1007/s10571-021-01078-3. Epub 2021 Apr 10.
3
Patients Stratification Strategies to Optimize the Effectiveness of Scavenging Biogenic Aldehydes: Towards a Neuroprotective Approach for Parkinson's Disease.
患者分层策略以优化生物源性醛类清除的效果:帕金森病的神经保护方法。
Curr Neuropharmacol. 2021;19(10):1618-1639. doi: 10.2174/1570159X19666210203162617.
4
Alzheimer Disease and Selected Risk Factors Disrupt a Co-regulation of Monoamine Oxidase-A/B in the Hippocampus, but Not in the Cortex.阿尔茨海默病及特定风险因素破坏海马体中但非皮质中单胺氧化酶A/B的共同调节。
Front Neurosci. 2018 Jun 26;12:419. doi: 10.3389/fnins.2018.00419. eCollection 2018.
5
Microdialysis: the Key to Physiologically Based Model Prediction of Human CNS Target Site Concentrations.微透析:预测人体中枢神经系统靶部位浓度的生理基础模型的关键。
AAPS J. 2017 Jul;19(4):891-909. doi: 10.1208/s12248-017-0050-3. Epub 2017 Mar 9.
6
Catechol and aldehyde moieties of 3,4-dihydroxyphenylacetaldehyde contribute to tyrosine hydroxylase inhibition and neurotoxicity.3,4-二羟基苯乙醛的儿茶酚和醛基部分会导致酪氨酸羟化酶抑制和神经毒性。
Brain Res. 2012 Sep 20;1474:100-9. doi: 10.1016/j.brainres.2012.07.048. Epub 2012 Jul 31.
7
Inhibition and covalent modification of tyrosine hydroxylase by 3,4-dihydroxyphenylacetaldehyde, a toxic dopamine metabolite.3,4-二羟苯乙醛抑制并共价修饰酪氨酸羟化酶,后者是一种毒性多巴胺代谢物。
Neurotoxicology. 2011 Aug;32(4):471-7. doi: 10.1016/j.neuro.2011.03.013. Epub 2011 Apr 14.
8
Behavioral disinhibition and reduced anxiety-like behaviors in monoamine oxidase B-deficient mice.单胺氧化酶 B 缺陷型小鼠的行为抑制缺失和焦虑样行为减少。
Neuropsychopharmacology. 2009 Dec;34(13):2746-57. doi: 10.1038/npp.2009.118. Epub 2009 Aug 26.
9
Perspectives on MAO-B in aging and neurological disease: where do we go from here?衰老与神经疾病中MAO-B的研究展望:我们将何去何从?
Mol Neurobiol. 2004 Aug;30(1):77-89. doi: 10.1385/MN:30:1:077.
10
Neuroprotective strategies in Parkinson's disease : an update on progress.帕金森病的神经保护策略:进展更新
CNS Drugs. 2003;17(10):729-62. doi: 10.2165/00023210-200317100-00004.